PATENT AND TECHNOLOGY LICENSE AGREEMENTPatent and Technology License Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
THIS AGREEMENT (“AGREEMENT”) is made by and between the BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (“MDA”), a component institution of the SYSTEM and INTRON THERAPEUTICS, INC., a Texas corporation having a principal place of business located at 301 Congress, Suite 2025, Austin, Texas 78701 (“LICENSEE”).
GENPREX, INC. WARRANT AGREEMENT Effective as of December 17, 2015Warrant Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, DABS Advanced Biotech Solutions, LLC, or its successors and permitted assigns pursuant to the terms hereof (the “Warrantholder”), is entitled to purchase from Genprex, Inc., a Delaware corporation (the “Corporation”), subject to the terms set forth below, 15,365 fully paid and non-assessable shares (subject to adjustment as provided herein) (the “Warrant Shares”) of the Corporation’s Non-Voting Common Stock, par value $0.001 per share (the “Non-Voting Common Stock”), at a purchase price of $32.54 in cash per Warrant Share (the “Exercise Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. The term “Warrant Agreement” as used herein shall refer to this Warrant Agreement, as the same may be amended or amended and restated.
TECHNOLOGY SUBLICENSE AGREEMENTTechnology Sublicense Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations
This Sublicense Agreement (“Agreement”) is made effective this 7th day of March, 2007, by and between Introgen Therapeutics, Inc., a Delaware corporation (“Sublicensor”), and Introgen Research Institute, Inc., a Texas corporation (“Sublicensee”).
ASSIGNMENT AND COLLABORATION AGREEMENTAssignment and Collaboration Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations
This Assignment and Collaboration Agreement (“Agreement”) is made effective on the 13th day of April 2009, by and between Assignor and Assignee. For purposes hereof, capitalized terms herein have the meanings set forth on Annex A hereto.
TECHNOLOGY SUBLICENSE AGREEMENTTechnology Sublicense Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations
This Sublicense Agreement (“Agreement”) is made effective this 1st day of June, 2011, by and between Convergen LifeSciences, Inc., a Delaware corporation (“Sublicensor”), and Introgen Research Institute, Inc., a Texas corporation (“Sublicensee”).
AMENDED COLLABORATION AND ASSIGNMENT AGREEMENTCollaboration and Assignment Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
This Amendment Collaboration and Assignment Agreement (“Agreement”) is made by and between Introgen Research Institute, Inc., a Texas corporation (“IRI”) and Convergen LifeSciences, Inc., a Delaware corporation (“Convergen”) to be effective this first day of July, 2011.
EMPLOYMENT AGREEMENTEmployment Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made effective the 23rd day of October, 2016 (the “Effective Date”), by and between JULIEN L. PHAM, M.D., M.P.H. (the “Employee”), and GENPREX, INC., a Delaware corporation (“Genprex”).
AMENDMENT NO. 3 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT DATED JULY 31,1994Patent and Technology License Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations
This is AMENDMENT NO. 3 effective this 4th day of October, 2001, to the Patent and Technology License Agreement dated July 31, 1994, (AGREEMENT) and Amendment No. 1 to the Patent and Technology License Agreement dated September 1, 1996 (AMENDMENT NO. 1), and Amendment No. 2 to the Patent and Technology License Agreement dated August 11, 1997 (AMENDMENT NO. 2), is between THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (MDA), located at 1515 Holcombe Boulevard, Houston, Texas, and which is a component institution of THE UNIVERSITY OF TEXAS SYSTEM (SYSTEM) which is governed by a BOARD OF REGENTS (BOARD) and INTROGEN THERAPEUTICS, INC., a Texas corporation, located at 301 Congress Avenue, Suite 1850, Austin, Texas 78701 (LICENSEE).
TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
THIS TECHNOLOGY LICENSE AGREEMENT (“Agreement”) dated as of February 26, 2010 (“Effective Date”), is entered into between Introgen Research Institute, Inc., a Delaware corporation, (“IRI” or “Licensor”) and P53, Inc., a Delaware corporation (“P53” or “Licensee”). BACKGROUND
AGREEMENT Between CONVERGEN LIFESCIENCES, INC. And THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTERResearch and Development • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations
This Agreement (“Agreement”) is entered into on the 14th day of September 2010, by and between Convergen LifeSciences, Inc., located at 9015 Mountain Ridge Drive, Suite 250, Austin, Texas, hereinafter referred to as the Project Sponsor, and the University of Texas M. D. Anderson Cancer Center, located at 1515 Holcombe Blvd., Houston, TX 77030 hereinafter referred to as the Contractor, a member institution of The University of Texas System, hereinafter referred to as System, is for the performance of certain work and services in connection with:
TEXAS EMERGING TECHNOLOGY FUND AWARD AND SECURITY AGREEMENT BETWEEN THE STATE OF TEXAS AND CONVERGEN LIFESCIENCES, INC.Texas Emerging Technology Fund Award and Security Agreement • August 18th, 2017 • Genprex, Inc. • Pharmaceutical preparations • Texas
THIS TEXAS EMERGING TECHNOLOGY FUND AWARD AND SECURITY AGREEMENT (this “Agreement”) shall be effective as of the last date of execution hereof by the parties hereto, as reflected on the signature page hereto (the “Effective Date”), and is by and between the State of Texas, acting by and through the Office of the Governor Economic Development and Tourism (the “OOGEDT”) and Convergen LifeSciences, Inc., a Delaware corporation (the “Company”).
